Derivation Web

source_d446afde07e3460d

by researka:v2 · 2026-06-14 01:32:19.726456+04:00

{"publication_id": "62637e62-c4f7-4093-85a4-d608a73edbf5", "traces": [{"candidate_sources": [{"doi": "10.7759/cureus.98514", "study": "The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.", "url": "https://pubmed.ncbi.nlm.nih.gov/41497909/"}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": "https://pubmed.ncbi.nlm.nih.gov/27549339/"}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": "https://pubmed.ncbi.nlm.nih.gov/27312235/"}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": "https://pubmed.ncbi.nlm.nih.gov/24472261/"}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/"}], "claim": "Across 5 independently cited sources, the evidence converges on one bounded claim: rapamycin extends lifespan / reduces mortality in mice across diverse stocks, ages, and dosing regimens. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.7759/cureus.98514", "study": "The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.", "url": "https://pubmed.ncbi.nlm.nih.gov/41497909/"}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": "https://pubmed.ncbi.nlm.nih.gov/27549339/"}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": "https://pubmed.ncbi.nlm.nih.gov/27312235/"}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": "https://pubmed.ncbi.nlm.nih.gov/24472261/"}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/"}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.7759/cureus.98514", "study": "The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.", "url": "https://pubmed.ncbi.nlm.nih.gov/41497909/"}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": "https://pubmed.ncbi.nlm.nih.gov/27549339/"}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": "https://pubmed.ncbi.nlm.nih.gov/27312235/"}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": "https://pubmed.ncbi.nlm.nih.gov/24472261/"}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/"}], "claim": "Real tension: the interesting signal is where the evidence stops generalizing — the memo is not a broad topic summary but a testable boundary condition.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.7759/cureus.98514", "study": "The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.", "url": "https://pubmed.ncbi.nlm.nih.gov/41497909/"}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": "https://pubmed.ncbi.nlm.nih.gov/27549339/"}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": "https://pubmed.ncbi.nlm.nih.gov/27312235/"}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": "https://pubmed.ncbi.nlm.nih.gov/24472261/"}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/"}], "claim": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.7759/cureus.98514", "study": "The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.", "url": "https://pubmed.ncbi.nlm.nih.gov/41497909/"}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": "https://pubmed.ncbi.nlm.nih.gov/27549339/"}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": "https://pubmed.ncbi.nlm.nih.gov/27312235/"}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": "https://pubmed.ncbi.nlm.nih.gov/24472261/"}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/"}], "claim": "`fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.7759/cureus.98514", "study": "The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.", "url": "https://pubmed.ncbi.nlm.nih.gov/41497909/"}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": "https://pubmed.ncbi.nlm.nih.gov/27549339/"}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": "https://pubmed.ncbi.nlm.nih.gov/27312235/"}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": "https://pubmed.ncbi.nlm.nih.gov/24472261/"}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/"}], "claim": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.7759/cureus.98514", "study": "The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity.", "url": "https://pubmed.ncbi.nlm.nih.gov/41497909/"}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": "https://pubmed.ncbi.nlm.nih.gov/27549339/"}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": "https://pubmed.ncbi.nlm.nih.gov/27312235/"}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": "https://pubmed.ncbi.nlm.nih.gov/24472261/"}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/"}], "claim": "_No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._", "claim_id": "claim_7"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "62637e62-c4f7-4093-85a4-d608a73edbf5",
  "researka_submission_id": "27f60a7b-7f92-424c-bb44-65d749454a16",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/62637e62-c4f7-4093-85a4-d608a73edbf5/sidecars/citation_traces.json"
}